Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
305.3 EUR | +1.56% | +1.04% | -5.65% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.98 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.65% | 23.57B | - | ||
-4.72% | 184B | C+ | ||
-2.83% | 103B | C | ||
-5.01% | 67.59B | A | ||
+15.53% | 46.93B | B- | ||
-8.53% | 43.87B | B- | ||
+8.28% | 41.2B | B+ | ||
+17.67% | 30.47B | B | ||
+13.59% | 24.16B | A- | ||
-11.17% | 22.26B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- WST Stock
- WPS Stock
- Ratings West Pharmaceutical Services, Inc.